LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA

This is the authors' abstract. We don't add key points for this paper.

The unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell-free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.